Wet AMD sufferers unaware of pre-existing AMD

Article

Current screening of patients with age-related macular degeneration (AMD) does not sufficiently identify those patients most at risk of wet AMD and hence is unable to prevent its development, according to a report published in the June 2008 issue of Eye.

Current screening of patients with age-related macular degeneration (AMD) does not sufficiently identify those patients most at risk of wet AMD and hence is unable to prevent its development, according to a report published in the June 2008 issue of Eye.

Itay Chowers, MD of the Hadassah-Hebrew University Medical Center, Israel and colleagues conducted a retrospective analysis of NVAMD subjects (n=268) and compared characteristics between those subjects who were aware of their AMD before the NVAMD diagnosis (n=83), and those who were not (n=185).

The researchers found that there were no significant differences between the two groups in terms of demographic characteristics, visual acuity, lesion size and lesion composition. Patients who were not previously aware of their AMD were more likely to have a history of smoking (41%) than those who were aware (26%); patients with a positive family history of AMD were more likely to be aware of their own AMD before the NVAMD diagnosis (20%) than those who did not (10%).

The team concluded that the majority of patients receiving an NVAMD diagnosis were previously unaware that they had AMD, although early AMD detection may not entail detection of treatable choroidal neovascularization lesions.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
Related Content
© 2025 MJH Life Sciences

All rights reserved.